Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a clinical trial.

Poor adherence, resulting in suboptimal treatment outcomes, is common due to long-term treatment.

Who Took Part

The age groups tagged for this paper are children and teenagers, both men and women.

Patients performed repeated injections of test medium into a foam cushion.

Patients or guardians completed a questionnaire on pen handling.

How the Study Was Run

In design terms this was an open-label and pilot study.

Being open-label, the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study did not mask who received what.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

What Was Measured

Poor adherence, resulting in suboptimal treatment outcomes, is common due to long-term treatment.

The subject headings attached to it are Age Factors, Cohort Studies, Drug Delivery Systems, Equipment Design, Growth Disorders, Human Growth Hormone and Materials Testing.

What This Means in Plain Language

The paper is an open-label and pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2011 (Journal of pediatric endocrinology & metabolism : JPEM), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.